Study shows these Alzheimer's drug candidates reverse broader ageing

Image
ANI
Last Updated : Dec 15 2019 | 3:45 PM IST

A new study suggests that the Alzheimer's drug candidates CMS121 and J147 may be useful for treating a broader array of conditions and points out a new pathway that links normal ageing to Alzheimer's disease.

The research was published in the journal eLife.

According to Pamela Maher, a senior staff scientist at Salk and a co-corresponding author of the new paper, "This study further validated these two compounds CMS121 and J147, not only as Alzheimer's drug candidates but also as potentially more widely useful for their anti-ageing effects,"

Old age is the biggest risk factor for Alzheimer's disease -- above the age of 65, a person's risk of developing the disease doubles about every five years. However, at a molecular level, scientists aren't sure what occurs in the brain with ageing that contributes to Alzheimer's.

"The contribution of old age-associated detrimental processes to the disease has been largely neglected in Alzheimer's disease drug discovery," says Antonio Currais, a Salk staff scientist and first author of the new paper.

Maher and David Schubert, the head of Salk's Cellular Neurobiology Lab, previously developed CMS121 and J147, variants of plant compounds with medicinal properties.

Both compounds tested positive for their ability to keep neurons alive when exposed to cellular forms of stress related to ageing and Alzheimer's disease. Since then, the researchers have used the drug candidates to treat Alzheimer's in animal models of the disease.

But experiments revealing exactly how the compounds work suggested that they were targeting molecular pathways also known to be important in longevity and ageing.

"The bottom line was that these two compounds prevent molecular changes that are associated with ageing," says Maher.

"There was already some data from human studies that the function of mitochondria is negatively impacted in ageing and that it's worse in the context of Alzheimer's," says Maher. "This helps solidify that link.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 15 2019 | 3:32 PM IST

Next Story